HURA•benzinga•
TuHURA Biosciences And Kineta Present Updated Results From Kineta's Phase I-II Study Of KVA12123 And TuHURA's Mechanism Of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure In Advanced Melanoma
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 28, 2025 by benzinga